Alberta Public Health Disease Management Guidelines

Multisystem Inflammatory Syndrome in Children (MIS-C)

Alberta 🗖

Ministry of Health, Government of Alberta

May 2020

Multisystem Inflammatory Syndrome in Children (MIS-C), Novel Public Health Disease Management Guideline

https://www.alberta.ca/notifiable-disease-guidelines.aspx

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without written permission of Alberta Health, Government of Alberta.

© Copyright of this document and its contents belongs to the Government of Alberta.

For further information on the use of this protocol contact:

Health.CD@gov.ab.ca

Health and Wellness Promotion Branch

Public Health and Compliance Branch

Alberta Health

Case Definition

NOTE: Alberta Health will update this guideline as new information becomes available

Preliminary Case

Children and adolescents 0-19 years of age with fever ≥ 3 days

AND two of the following:

- Rash or bilateral non-purulent conjunctivitis or muco-cutaneous inflammation signs (oral, hands or feet)
- Hypotension or shock
- Features of myocardial dysfunction, or pericarditis, or valvulitis, or coronary abnormalities (ECHO findings or elevated Troponin/NT-proBNP)
- Evidence of coagulopathy (abnormal PT, PTT, elevated d-Dimers)
- Acute gastrointestinal problems (diarrhea, vomiting or abdominal pain)

AND

• Elevated markers of inflammation such as ESR, C-reactive protein or procalcitonin

AND

 No other obvious microbial cause of inflammation, including bacterial sepsis, staphylococcal or streptococcal shock syndromes

WITH OR WITHOUT^(A)

 Evidence of COVID (RT-PCR, antigen test or serology positive) or likely contact with patients with COVID-19.

^(A) This criteria is optional at this time in Alberta to ensure the case definition is sensitive enough to include all cases of concern. When the meaning and availability of serological testing is more completely understood this criterial may become a required criteria. Any information about COVID-19 testing results and any epidemiological link should be included in the appropriate sections of the <u>MIS-C Case Report Form</u>.

Reporting Requirements

1. Physicians

All physicians shall notify the Medical Officer of Health (MOH) (or designate) of the zone, of all cases that meet the preliminary case definition in the prescribed form as determined by the MOH within 48 hours (two business days) and include:

- Age
- Date of birth
- Gender;
- Personal health number;
- Positive laboratory report (if applicable); and
- Other relevant clinical/epidemiological information

2. Alberta Health Services and First Nations Inuit Health Branch

- The MOH (or designate) of the zone where the case currently resides shall notify the CMOH (or designate) via email (<u>health.cd@gov.ab.ca</u>) of all preliminary cases within 48 hours (two business days) of initial notification and include:
 - Age
 - Date of birth
 - Sex and
 - Personal health number
 - Positive laboratory report/s (if applicable) and
 - Other relevant clinical/epidemiological information.
- The MOH (or designate) of the zone where the case currently resides shall forward the <u>MIS-C Case report Form</u> for all preliminary cases to the CMOH (or designate) within seven days of initial notification as per usual communicable disease reporting processes.
- For out-of-province and out-of-country preliminary cases, the following information should be forwarded to the CMOH (or designate) via email (health.cd@gov.ab.ca) and include:
 - name,
 - date of birth,
 - out-of-province health care number,
 - out-of-province address and phone number,
 - any positive laboratory report/s, and
 - other relevant clinical / epidemiological information.

ANNEX B: Revision History

Revision Date	Document Section	Description of Revision
2020-05-27	Case Definition	• Interim case definition adapted from WHO ⁽¹⁾ included.

References

1. World Health Orgranization (WHO). Multisystem inflammatory syndrome in children and adolescents with COVID-19 [Internet]. 2020 [cited 2020 May 28]. Available from: https://www.who.int/publications-detail/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19